Abstract
Currently, there are no consistent procedures for transitioning adolescents from paediatric to adult cystic fibrosis (CF) care, and little empirical evidence exists on the best practices for transition. Given increased survival among patients with CF, a more formalised transition process is necessary to ensure continuity of care across the lifespan. This chapter reviews current transition practices and makes specific recommendations for more gradual, developmentally appropriate procedures involving all members of the CF care team. To ensure successful transition, providers should be aware of the normative milestones of adolescence and emerging adulthood, and how CF disrupts youths' navigation of these milestones. Age-appropriate guidance should be given to adolescents and their families in gradual doses, beginning in early childhood and continuing until early adulthood. Importantly, the success of these recommendations depends on clear and active communication between paediatric and adult care teams, parents, and adolescents.
| Original language | English |
|---|---|
| Pages (from-to) | 272-285 |
| Number of pages | 14 |
| Journal | European Respiratory Monograph |
| Volume | 64 |
| DOIs | |
| State | Published - Jan 1 2014 |
Fingerprint
ASJC Scopus subject areas
- Pulmonary and Respiratory Medicine
Cite this
Transition from paediatric to adult cystic fibrosis care : A developmental framework. / Madan, Anjana S.; Alpern, Adrianne N.; Quittner, Alexandra.
In: European Respiratory Monograph, Vol. 64, 01.01.2014, p. 272-285.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Transition from paediatric to adult cystic fibrosis care
T2 - A developmental framework
AU - Madan, Anjana S.
AU - Alpern, Adrianne N.
AU - Quittner, Alexandra
PY - 2014/1/1
Y1 - 2014/1/1
N2 - Currently, there are no consistent procedures for transitioning adolescents from paediatric to adult cystic fibrosis (CF) care, and little empirical evidence exists on the best practices for transition. Given increased survival among patients with CF, a more formalised transition process is necessary to ensure continuity of care across the lifespan. This chapter reviews current transition practices and makes specific recommendations for more gradual, developmentally appropriate procedures involving all members of the CF care team. To ensure successful transition, providers should be aware of the normative milestones of adolescence and emerging adulthood, and how CF disrupts youths' navigation of these milestones. Age-appropriate guidance should be given to adolescents and their families in gradual doses, beginning in early childhood and continuing until early adulthood. Importantly, the success of these recommendations depends on clear and active communication between paediatric and adult care teams, parents, and adolescents.
AB - Currently, there are no consistent procedures for transitioning adolescents from paediatric to adult cystic fibrosis (CF) care, and little empirical evidence exists on the best practices for transition. Given increased survival among patients with CF, a more formalised transition process is necessary to ensure continuity of care across the lifespan. This chapter reviews current transition practices and makes specific recommendations for more gradual, developmentally appropriate procedures involving all members of the CF care team. To ensure successful transition, providers should be aware of the normative milestones of adolescence and emerging adulthood, and how CF disrupts youths' navigation of these milestones. Age-appropriate guidance should be given to adolescents and their families in gradual doses, beginning in early childhood and continuing until early adulthood. Importantly, the success of these recommendations depends on clear and active communication between paediatric and adult care teams, parents, and adolescents.
UR - http://www.scopus.com/inward/record.url?scp=84905735626&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84905735626&partnerID=8YFLogxK
U2 - 10.1183/1025448x.10010413
DO - 10.1183/1025448x.10010413
M3 - Article
VL - 64
SP - 272
EP - 285
JO - European Respiratory Monograph
JF - European Respiratory Monograph
SN - 1025-448X
ER -